NAVIGATE-Kidney Program for Kidney Disease
(NAV-Kidney Trial)
Trial Summary
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Navigate-Kidney CHW for kidney disease?
Research shows that patient navigator programs and enhanced personal health records can improve healthcare quality for chronic kidney disease (CKD) patients. Additionally, adherence to a multidisciplinary renal health program has been effective in reducing the need for dialysis and lowering mortality rates in CKD patients.12345
What safety data exists for the NAVIGATE-Kidney Program for Kidney Disease?
The available research highlights that chronic kidney disease (CKD) patients are at high risk for safety issues, such as medication errors and adverse events, due to impaired kidney function and frequent healthcare interactions. While specific safety data for the NAVIGATE-Kidney Program is not provided, the general safety concerns for CKD patients are well-documented, emphasizing the need for careful monitoring and management to prevent harm.16789
How is the NAVIGATE-Kidney CHW treatment different from other kidney disease treatments?
The NAVIGATE-Kidney CHW treatment is unique because it involves patient navigators who help coordinate care, address system barriers, and educate patients, which is not a standard approach in kidney disease management. This program aims to improve outcomes by providing personalized support and education, similar to successful strategies used in cancer care.12101112
What is the purpose of this trial?
The overarching goal of this project is to refine and adapt previous work on the NAVIGATE-Kidney project for Latinx with CKD. The investigators hypothesize that the multilevel NAVIGATE-Kidney program intervention will reduce the rate of central venous catheter use at KRT start (primary outcome), increase the rate of optimal KRT starts (secondary outcome), increase patient activation, and reduce decisional conflict (patient-centered outcomes) for Latinx with advanced CKD. The project will have four (4) aims.
Research Team
Lilia Cervantes, MD
Principal Investigator
University of Colorado-Anschutz SOM-Hospital Medicine
Eligibility Criteria
The NAVIGATE Kidney trial is for Latinx individuals with advanced Chronic Kidney Disease (CKD). It aims to improve kidney health outcomes by testing a program called NAVIGATE-Kidney. Specific eligibility criteria are not provided, but typically participants would need to meet certain health conditions related to CKD.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the NAVIGATE-Kidney intervention with support from a community health worker every 2 weeks for 3 months, followed by monthly visits
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of patient-centered outcomes and implementation outcomes
Economic Evaluation
Economic evaluation to determine the cost-effectiveness of the NAVIGATE-Kidney intervention
Treatment Details
Interventions
- Navigate-Kidney CHW
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
Weill Medical College of Cornell University
Collaborator
University of New Mexico
Collaborator
Denver Health and Hospital Authority
Collaborator